Editas Medicine, Inc. (EDIT) · Oct 8, 2026 · Other events
Phase 1/2 trial approved — Australian ethics approval and CTN completed
Editas Medicine received approval to start its EDIT-401 hyperlipidemia trial, advancing its lead program toward first-in-human data in 2027.
Editas is a clinical-stage gene-editing company concentrating its in-vivo strategy around EDIT-401, a one-time LDL-lowering treatment that has shown roughly 90% reductions in several atherogenic lipoproteins in non-human primates. The company had already framed 2026 as the year to move EDIT-401 into first-in-human testing, with its second-quarter update pointing to an Australian regulatory submission and a 2027 data update.
The key milestone was achieved: Editas now has the approvals needed to begin its Phase 1/2 Strive trial in Australia, after receiving ethics approval and completing the Clinical Trial Notification process with Australia’s regulator. 〔0〕 That moves EDIT-401 from preclinical development into human testing, which is the central business transition the company has been working toward.
This is progress, but not a major surprise: the direction was already expected because Editas had previously said it was on track to submit the Australian notification and initiate the first-in-human study in 2026. The new information is the completed approval and the clearer trial timetable, rather than an unexpected change in strategy.
The evidence remains preclinical, not clinical: the filing highlights approximately 90% reductions in LDL-C, Lp(a), and ApoB in non-human primates, with LDL-C reduction maintained for 10 months in an ongoing study. 〔1〕 Those results support the rationale for testing EDIT-401, but the trial must now establish whether the editing approach is safe, tolerable, and effective in people.
The next value-bearing readouts are now defined: Editas expects initial safety and tolerability data in the first quarter of 2027, followed by topline safety and efficacy data from the dose-finding portion later in 2027. 〔2〕 The November 8 AHA presentation will add durability detail, but it will still be animal data rather than proof of human benefit.
Bottom line: This advances Editas’ main program exactly where the company said it was heading, making the update mildly positive but partly anticipated. The story now shifts from regulatory preparation to whether EDIT-401 can produce a credible first-in-human safety and efficacy signal in 2027.
AHA durability data, November 8; initial safety data, Q1 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!